Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

Journal of Clinical Microbiology

Volumn 49, Issue 1, 2011, Pages 396-399

  Pfaller, Michael A ^a   Moet, Gary J ^a   Messer, Shawn A ^a   Jones, Ronald N ^a,b   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASIA; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CATHETER INFECTION; CLAVISPORA LUSITANIAE; DISEASE SURVEILLANCE; EUROPE; FUNGAL STRAIN; GEOGRAPHY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NORTH AMERICA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; SPECIES DISTRIBUTION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; ECHINOCANDINS; FUNGEMIA; GEOGRAPHY; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 78650924029     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01398-10     Document Type: Article

References (22)

1. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
2. Chapeland-Leclerc, F., C. Hennequin, N. Papon, T. Noel, A. Girard, G. Socie, P. Ribaud, and C. Lacroix. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54:1360-1362.
3. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
4. CLSI. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. CLSI, Wayne, PA.
5. CLSI. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement. CLSI, Wayne, PA.
6. Diekema, D. J., S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, J. Kroeger, R. N. Jones, and M. A. Pfaller. 2009. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63:233-236.
7. Dodgson, K. J., A. R. Dodgson, D. Pujol, S. A. Messer, D. R. Soll, and M. A. Pfaller. 2005. Caspofungin resistant C. glabrata. Clin. Microbiol. Infect. 11: 364.
8. Garcia-Effron, G., D. J. Chua, J. R. Tomada, J. DiPersio, D. S. Perlin, M. Ghannoum, and H. Bonilla. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
9. Messer, S. A., R. N. Jones, and T. R. Fritsche. 2006. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Anti-microbial Surveillance Program (2003). J. Clin. Microbiol. 44:1782-1787.
10. Oxman, D. A., J. K. Chow, G. Frendl, S. Hadley, S. Hershkovitz, P. Ireland, L. A. McDermott, K. Tsai, F. M. Marty, D. P. Kontoyiannis, and Y. Golan. 2010. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65:1460-1465.
11. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743.
12. Pfaller, M. A., D. Andes, D. J. Diekema, A. Espinel-Ingroff, D. Sheehan, and the CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13: 180-195.
13. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44:3533-3538.
14. Pfaller, M. A., and D. J. Diekema. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
15. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
16. Pfaller, M. A., D. J. Diekema, D. Andes, M. C. Arendrup, S. D. Brown, M. Motyl, D. S. Perlin, and the CLSI Subcommittee for Antifungal Susceptibility Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat., in press.
17. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, D. Ellis, V. Tullio, A. Rodloff, W. Fu, and T. A. Ling. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
18. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messer, and R. J. Hollis. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.
19. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
20. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
21. Pfeiffer, C. D., G. Garcia-Effron, A. K. Zaas, J. R. Perfect, D. S. Perlin, and B. D. Alexander. 2010. Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol. 48:2373-2380.
22. Thompson, G. R., III, N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis, Jr., and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.